Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Share-based Compensation (2016 - 2025)

Iovance Biotherapeutics has reported Share-based Compensation over the past 12 years, most recently at $11.8 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $11.8 million for Q4 2025, down 61.85% from a year ago — trailing twelve months through Dec 2025 was $46.9 million (down 40.94% YoY), and the annual figure for FY2025 was $61.6 million, down 43.83%.
  • Share-based Compensation for Q4 2025 was $11.8 million at Iovance Biotherapeutics, down from $11.9 million in the prior quarter.
  • Over the last five years, Share-based Compensation for IOVA hit a ceiling of $31.0 million in Q3 2024 and a floor of $300000.0 in Q2 2023.
  • Median Share-based Compensation over the past 3 years was $13.1 million (2023), compared with a mean of $13.1 million.
  • Biggest five-year swings in Share-based Compensation: surged 10235.33% in 2024 and later tumbled 61.85% in 2025.
  • Iovance Biotherapeutics' Share-based Compensation stood at $14.4 million in 2023, then surged by 115.13% to $31.0 million in 2024, then tumbled by 61.85% to $11.8 million in 2025.
  • The last three reported values for Share-based Compensation were $11.8 million (Q4 2025), $11.9 million (Q3 2025), and $300000.0 (Q2 2025) per Business Quant data.